Literature DB >> 976320

A comparison of the vasodepressor effects of the cyclic effects of the cyclic endoperoxides PGG, and PGH2 with those of PGD2 and PGE2 in hypertensive and normotensive rats.

J M Armstrong, A L Boura, M Hamberg, B Samuelsson.   

Abstract

The vasodepressor actions of the cyclic endoperoxides PGG2 and PGH2 were compared with those of their products PGD2 and PGE2 using anaesthetised normotensive and genetically hypertensive rats. Given into the aortic arch of normotensives PGE2 was approximately 6 times more potent than PGH2 and 11 times more potent than PGG2 and PGD2. Hypertensive animals were 1.5-10 times more sensitive than normotensives to the depressor effects of PGG2 and PGH2, but their sensitivity to either PGD2 or PGE2 was similar. Thus in hypertensives the endoperoxides may be converted more readily to PGE2 and other products. In both types of rat PGG2 and PGH2 given intravenously were as active or more active than after intra-arterial. Therefore PGG2 and PGH2 may be converted more readily to more active products during passage through the lungs but whereas small doses of PGE2 are almost completely eliminated large doses may saturate uplmonary removal mechanisms.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 976320     DOI: 10.1016/0014-2999(76)90133-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Activation of prostaglandin E2 EP1 receptor increases arteriolar tone and blood pressure in mice with type 2 diabetes.

Authors:  Ibolya Rutkai; Attila Feher; Nora Erdei; Daniel Henrion; Zoltan Papp; Istvan Edes; Akos Koller; Gabor Kaley; Zsolt Bagi
Journal:  Cardiovasc Res       Date:  2009-03-19       Impact factor: 10.787

2.  The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure.

Authors:  J L Stock; K Shinjo; J Burkhardt; M Roach; K Taniguchi; T Ishikawa; H S Kim; P J Flannery; T M Coffman; J D McNeish; L P Audoly
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

3.  Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1alpha with those of prostaglandin E2 in rats and rabbits.

Authors:  J M Armstrong; N Lattimer; S Moncada; J R Vane
Journal:  Br J Pharmacol       Date:  1978-01       Impact factor: 8.739

4.  Regulation of arterial reactivity by concurrent signaling through the E-prostanoid receptor 3 and angiotensin receptor 1.

Authors:  Maria P Kraemer; Hyehun Choi; Jeff Reese; Fred S Lamb; Richard M Breyer
Journal:  Vascul Pharmacol       Date:  2016-05-31       Impact factor: 5.773

5.  Some factors affecting inactivation of prostaglandin E2 (PGE2) by the rat isolated perfused lung [proceedings].

Authors:  A L Boura; R D Murphy
Journal:  Br J Pharmacol       Date:  1978-03       Impact factor: 8.739

6.  Inhibition of the Prostaglandin Transporter PGT Lowers Blood Pressure in Hypertensive Rats and Mice.

Authors:  Yuling Chi; Jean-Francois Jasmin; Yoshinori Seki; Michael P Lisanti; Maureen J Charron; David J Lefer; Victor L Schuster
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

Review 7.  Raging the War Against Inflammation With Natural Products.

Authors:  Ali Attiq; Juriyati Jalil; Khairana Husain; Waqas Ahmad
Journal:  Front Pharmacol       Date:  2018-09-07       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.